Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Genomic imbalances associated with acquired resistance to platinum analogues.

Leyland-Jones B, Kelland LR, Harrap KR, Hiorns LR.

Am J Pathol. 1999 Jul;155(1):77-84.

2.

Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.

McKeage MJ, Raynaud F, Ward J, Berry C, O'Dell D, Kelland LR, Murrer B, Santabárabara P, Harrap KR, Judson IR.

J Clin Oncol. 1997 Jul;15(7):2691-700.

PMID:
9215842
3.

The cytotoxic action of four ammine/amine platinum(IV) dicarboxylates: a flow cytometric study.

Ormerod MG, Orr RM, O'Neill CF, Chwalinski T, Titley JC, Kelland LR, Harrap KR.

Br J Cancer. 1996 Dec;74(12):1935-43.

4.

Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.

Clarke SJ, Hanwell J, de Boer M, Planting A, Verweij J, Walker M, Smith R, Jackman AL, Hughes LR, Harrap KR, Kennealey GT, Judson IR.

J Clin Oncol. 1996 May;14(5):1495-503.

PMID:
8622063
5.

Tomudex (ZD1694): from concept to care, a programme in rational drug discovery.

Jackman AL, Boyle FT, Harrap KR.

Invest New Drugs. 1996;14(3):305-16. Review.

PMID:
8958186
6.

Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120.

Walton MI, Goddard P, Kelland LR, Thurston DE, Harrap KR.

Cancer Chemother Pharmacol. 1996;38(5):431-8.

PMID:
8765436
7.

Biotransformation of the platinum drug JM216 following oral administration to cancer patients.

Raynaud FI, Mistry P, Donaghue A, Poon GK, Kelland LR, Barnard CF, Murrer BA, Harrap KR.

Cancer Chemother Pharmacol. 1996;38(2):155-62.

PMID:
8616906
8.

Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.

Goddard PM, Orr RM, Valenti MR, Barnard CF, Murrer BA, Kelland LR, Harrap KR.

Anticancer Res. 1996 Jan-Feb;16(1):33-8.

PMID:
8615631
9.

cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines.

Ormerod MG, O'Neill C, Robertson D, Kelland LR, Harrap KR.

Cancer Chemother Pharmacol. 1996;37(5):463-71.

PMID:
8599870
10.

Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates.

Poon GK, Mistry P, Raynaud FI, Harrap KR, Murrer BA, Barnard CF.

J Pharm Biomed Anal. 1995 Nov;13(12):1493-8.

PMID:
8788134
11.

Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry.

Poon GK, Raynaud FI, Mistry P, Odell DE, Kelland LR, Harrap KR, Barnard CF, Murrer BA.

J Chromatogr A. 1995 Sep 29;712(1):61-6.

PMID:
8556156
13.

ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer.

Jackman AL, Farrugia DC, Gibson W, Kimbell R, Harrap KR, Stephens TC, Azab M, Boyle FT.

Eur J Cancer. 1995 Jul-Aug;31A(7-8):1277-82. Review.

PMID:
7577036
14.

2'-Deoxycytidine kinase deficiency is a major determinant of 2-chloro-2'-deoxyadenosine resistance in lymphoid cell lines

Orr RM, Talbot DC, Aherne WG, Fisher TC, Serafinowski P, Harrap KR.

Clin Cancer Res. 1995 Apr;1(4):391-8.

15.

A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.

Kelland LR, Barnard CF, Mellish KJ, Jones M, Goddard PM, Valenti M, Bryant A, Murrer BA, Harrap KR.

Cancer Res. 1994 Nov 1;54(21):5618-22.

17.

Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.

Orr RM, O'Neill CF, Nicolson MC, Barnard CF, Murrer BA, Giandomenico CM, Vollano JF, Harrap KR.

Br J Cancer. 1994 Sep;70(3):415-20.

18.

Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.

McKeage MJ, Kelland LR, Boxall FE, Valenti MR, Jones M, Goddard PM, Gwynne J, Harrap KR.

Cancer Res. 1994 Aug 1;54(15):4118-22.

19.

Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA.

Ormerod MG, O'Neill CF, Robertson D, Harrap KR.

Exp Cell Res. 1994 Apr;211(2):231-7.

PMID:
8143768
20.
22.

Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates.

McKeage MJ, Morgan SE, Boxall FE, Murrer BA, Hard GC, Harrap KR.

Cancer Chemother Pharmacol. 1994;33(6):497-503.

PMID:
8137461
23.

The antitumour activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor.

Jackman AL, Kimbell R, Brown M, Brunton L, Harrap KR, Wardleworth JM, Boyle FT.

Adv Exp Med Biol. 1994;370:185-8. Review. No abstract available.

PMID:
7660886
24.

European School of Oncology Task Force Report. New approaches in cancer pharmacology: drug design and development (Part 2).

Workman P, D'Incalci M, Bursch W, Harrap KR, Hawkins RE, Neidle S, Powis G.

Eur J Cancer. 1994;30A(8):1148-60. Review. No abstract available.

PMID:
7654448
25.
27.

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.

Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR.

Cancer Res. 1993 Jun 1;53(11):2581-6.

28.

Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents.

McKeage MJ, Morgan SE, Boxall FE, Murrer BA, Hard GC, Harrap KR.

Br J Cancer. 1993 May;67(5):996-1000.

29.
30.

Gamma-linked dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8- dideazafolate as antitumour agents.

Jackman AL, Bisset GM, Jodrell DI, Gibson W, Kimbell R, Bavetsias V, Calvert AH, Harrap KR, Stephens TC, Smith MN, et al.

Adv Exp Med Biol. 1993;338:579-84.

PMID:
8304184
32.

Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.

Balzarini J, De Clercq E, Serafinowski P, Dorland E, Harrap KR.

J Med Chem. 1992 Nov 27;35(24):4576-83.

PMID:
1335077
34.
35.

Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.

Kelland LR, Mistry P, Abel G, Freidlos F, Loh SY, Roberts JJ, Harrap KR.

Cancer Res. 1992 Apr 1;52(7):1710-6.

36.
37.

Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.

Kelland LR, Jones M, Abel G, Valenti M, Gwynne J, Harrap KR.

Cancer Chemother Pharmacol. 1992;30(1):43-50.

PMID:
1586979
38.
41.

Platinum coordination complexes which circumvent cisplatin resistance.

Harrap KR, Kelland LR, Jones M, Goddard PM, Orr RM, Morgan SE, Murrer BA, Abrams MJ, Giandomenico CM, Cobbleigh T.

Adv Enzyme Regul. 1991;31:31-43.

PMID:
1877393
42.

Historical aspects of glutathione and cancer chemotherapy.

Mistry P, Harrap KR.

Pharmacol Ther. 1991;49(1-2):125-32. Review.

PMID:
1852785
43.

Antimetabolites in cancer chemotherapy.

Clarke SJ, Jackman AL, Harrap KR.

Adv Exp Med Biol. 1991;309A:7-13. Review. No abstract available.

PMID:
1789273
44.

The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing mice.

Goddard PM, Jones M, Pollard LA, Valenti MR, Harrap KR.

Cancer Chemother Pharmacol. 1990;25(5):377-9.

PMID:
2155065
45.
46.

Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.

Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP, Harrap KR.

Br J Cancer. 1989 Apr;59(4):527-34.

47.

Thymidylate synthase: a target for anticancer drug design.

Harrap KR, Jackman AL, Newell DR, Taylor GA, Hughes LR, Calvert AH.

Adv Enzyme Regul. 1989;29:161-79.

PMID:
2633608
48.

Dinucleotide analogues as inhibitors of thymidine kinase, thymidylate kinase, and ribonucleotide reductase.

Davies LC, Stock JA, Barrie SE, Orr RM, Harrap KR.

J Med Chem. 1988 Jul;31(7):1305-8.

PMID:
2838631
49.

Inhibition of human leukaemic thymidylate kinase and L1210 ribonucleotide reductase by dinucleotides of adenosine and thymidine and their phosphonate analogues.

Orr RM, Davies LC, Stock JA, Taylor GA, Powles RL, Harrap KR.

Biochem Pharmacol. 1988 Feb 15;37(4):673-7.

PMID:
2829920
50.

The comparative tissues distribution of platinum and 14C in mice receiving 14C-labelled carboplatin.

Dible SE, Siddik ZH, Harrap KR.

Cancer Chemother Pharmacol. 1988;22(1):11-6.

PMID:
3293838

Supplemental Content

Loading ...
Support Center